Navigation Links
Intarcia Presents Positive ITCA 650 Phase 2 Study Results for Type 2 Diabetes at EASD
Date:9/22/2010

per year."

The phase 2 study enrolled 155 type 2 diabetes patients (51-53 patients/arm) across 50 centers in the United States on a stable treatment regimen of metformin. The study compared six different regimens to find the optimal dose range and regimen to take into phase 3:

  • ITCA 650 20 mcg/day for 24 weeks
  • ITCA 650 40 mcg/day for 24 weeks
  • ITCA 650 20 mcg/day for weeks 1 -12 followed by ITCA 650 60 mcg/day for weeks 13 -24
  • ITCA 650 40 mcg/day for weeks 1 -12 followed by ITCA 650 80 mcg/day for weeks 13 -24
  • Exenatide injection for weeks 1 -12 followed by ITCA 650 40 mcg/day for weeks 13 -24
  • Exenatide injection for weeks 1 -12 followed by ITCA 650 60 mcg/day for weeks 13 -24

  • Summary of week 12 resultsTreatment with ITCA 650 at doses of 20 mcg/day and 40 mcg/day resulted in significant reductions in HbA1c at week 12.  Initiating treatment with ITCA 650 20 mcg/day resulted in less frequent and less persistent nausea compared with ITCA 650 40 mcg/day and exenatide injection.  Nausea rates among patients receiving ITCA 650 at 40 mcg/day were similar to those receiving twice-daily injection of exenatide at 10 mcg BID.

    The phase 2 study also incorporated a quality of life (QOL) assessment (DM-SAT) completed by each patient prior to initiating treatment, at treatment week 8 and again at treatment week 20.  The results of week 8 assessment suggest that patients receiving either dose of ITCA 650 experienced significantly greater improvement in their quality of life compared to patients receiving twice-daily injections of exenatide.

    Summary of week 12 resultsTreatment Arms
    Weeks 1 – 12

    ITCA 650 20 mcg/d

    ITCA 650 40 mcg/dExenatide InjectionMean baseline HbA1c (%)

    7.90

    8.00

    8.01Mean week 12 HbA1c (%)

    6.94

    6.96

    7.19Mean change

    -0.96*

    -1.04*

    -0.82*Nausea ratesweek 1

    25%

    37%'/>"/>

    SOURCE Intarcia Therapeutics, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related medicine technology :

    1. Intarcia Therapeutics, Inc. Announces Completion of Enrollment of ITCA 650 Phase 1b Study for the Treatment of Type 2 Diabetes
    2. Intarcia Therapeutics Names Kurt Graves Executive Chairman to Advance Strategic Interests and Broaden Commercial Goals
    3. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
    4. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
    5. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
    6. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
    7. CEL-SCI Presents Data for CEL-1000 as a Vaccine Adjuvant with Recombinant Hepatitis B Virus Protein
    8. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
    9. Targanta Presents First Data Demonstrating In Vitro Activity and In Vivo Efficacy of Prodrugs in Osteomyelitis Models
    10. Wyeth Presents Phase 3 Fracture Data for Bazedoxifene, an Investigational Therapy for Osteoporosis
    11. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:10/31/2014)... Investor-Edge has initiated coverage on the ... Laboratories (NYSE: ABT ), Hologic Inc. (NASDAQ: ... and Covidien PLC (NYSE: COV). Free research on these five ... The US markets on Thursday, October 30, 2014, ended on ... at 17,195.42, up 1.30% and the NASDAQ Composite closed at ...
    (Date:10/31/2014)...  Australian biopharmaceutical company Specialised Therapeutics Australia (STA) is ... in combination with gemcitabine, will be reimbursed via the ... cancer from 1 November. In ... th most common cause of cancer mortality. Pancreatic ... the lowest 5-year survival of all common cancers at ...
    (Date:10/31/2014)... 31, 2014 Today, Analysts Review ... CELG ), Bristol-Myers Squibb Co. (NYSE: ... ), Sanofi SA (NYSE: SNY ) and ... notes ahead of publication. To reserve complementary membership, limited ... ,Celgene Corporation Research Reports ,On October 23, 2014, Celgene ...
    Breaking Medicine Technology:Health Care Equipment Stocks Technical Insight - Medtronic, Abbott Laboratories, Hologic, ResMed, and Covidien 2Health Care Equipment Stocks Technical Insight - Medtronic, Abbott Laboratories, Hologic, ResMed, and Covidien 3Health Care Equipment Stocks Technical Insight - Medtronic, Abbott Laboratories, Hologic, ResMed, and Covidien 4Health Care Equipment Stocks Technical Insight - Medtronic, Abbott Laboratories, Hologic, ResMed, and Covidien 5Specialised Therapeutics Australia Announces Breakthrough Cancer Drug Abraxane(R) to be PBS Listed for Metastatic Pancreatic Cancer 2Specialised Therapeutics Australia Announces Breakthrough Cancer Drug Abraxane(R) to be PBS Listed for Metastatic Pancreatic Cancer 3Specialised Therapeutics Australia Announces Breakthrough Cancer Drug Abraxane(R) to be PBS Listed for Metastatic Pancreatic Cancer 4Specialised Therapeutics Australia Announces Breakthrough Cancer Drug Abraxane(R) to be PBS Listed for Metastatic Pancreatic Cancer 5Specialised Therapeutics Australia Announces Breakthrough Cancer Drug Abraxane(R) to be PBS Listed for Metastatic Pancreatic Cancer 6Specialised Therapeutics Australia Announces Breakthrough Cancer Drug Abraxane(R) to be PBS Listed for Metastatic Pancreatic Cancer 7Specialised Therapeutics Australia Announces Breakthrough Cancer Drug Abraxane(R) to be PBS Listed for Metastatic Pancreatic Cancer 8Financial Results, Acquisition Agreement, and Legal Issue Update - Research Reports on Celgene, Bristol-Myers, UnitedHealth, Sanofi and Actavis 2Financial Results, Acquisition Agreement, and Legal Issue Update - Research Reports on Celgene, Bristol-Myers, UnitedHealth, Sanofi and Actavis 3Financial Results, Acquisition Agreement, and Legal Issue Update - Research Reports on Celgene, Bristol-Myers, UnitedHealth, Sanofi and Actavis 4Financial Results, Acquisition Agreement, and Legal Issue Update - Research Reports on Celgene, Bristol-Myers, UnitedHealth, Sanofi and Actavis 5Financial Results, Acquisition Agreement, and Legal Issue Update - Research Reports on Celgene, Bristol-Myers, UnitedHealth, Sanofi and Actavis 6
    ... Jan. 27, 2011 Significant flooding occurred in many ... January 2011.  Thousands of residents were affected.  A disaster ... on 29 December 2010, by Premier of Queensland, Anna ... in to help their fellow citizens clean-up in the ...
    ... China and ROCKVILLE, Md., Jan. 26, 2011 /PRNewswire-Asia/ -- Synutra ... formula company in China and a producer, marketer and seller ... that it plans to release its financial results for the ... 2011 after market close. The Company will ...
    Cached Medicine Technology:DSM Joins International Response to Flooding in Australia 2DSM Joins International Response to Flooding in Australia 3Synutra to Announce Third Quarter Fiscal 2011 Financial Results 2
    (Date:10/31/2014)... Daily Gossip writes in its Xtreme Fat Loss review that ... loss program ever developed. It promises to provide users the ... no wonder after all that this has become the most ... and workout fat loss program was created by Joel Marion, ... the author of this fat loss system, the method can ...
    (Date:10/31/2014)... Lake City, UT (PRWEB) October 31, 2014 ... announce the new Activz Silver line offering ... and cleansing wipes. For over a century, silver has ... formula found in Activz Silver products is the most ... U.S. patents, has a unique chemical structure that supports ...
    (Date:10/31/2014)... In terms of duration of treatment and cost, ... from accelerated partial breast irradiation (APBI) with proton ... new research from The University of Texas MD ... a cost analysis study based on typical patient ... allowable charges for eight different types of partial ...
    (Date:10/31/2014)... Colorado (PRWEB) October 31, 2014 The ... that this workout program was developed by Dan Long, ... become well-known as a fitness professional and life coach. ... fat and having toned muscles is not impossible , ... based on suspension training. Suspension training promises efficiency when ...
    (Date:10/31/2014)... NY (PRWEB) October 31, 2014 ... the most remarkable gifts of life — building a ... matching extraordinary surrogate mothers and donors with hopeful intended ... in unforeseen circumstances. , It’s a collective aptitude of ... agencies, surrogacy lawyers, and fertility clinics that help provide ...
    Breaking Medicine News(10 mins):Health News:Xtreme Fat Loss Diet Review Reveals How to Transform Your Body in 25 Days 2Health News:New Collection of Nano-particle Natural Silver Products by Activz Whole-Food Nutrition 2Health News:New Collection of Nano-particle Natural Silver Products by Activz Whole-Food Nutrition 3Health News:New Collection of Nano-particle Natural Silver Products by Activz Whole-Food Nutrition 4Health News:Proton therapy shown to be less costly than some alternative radiotherapy techniques 2Health News:Proton therapy shown to be less costly than some alternative radiotherapy techniques 3Health News:Suspension Revolution Review Reveals Dan Long's New Suspension Workout Plan 2Health News:Over 800 New Surrogate Mother Members at FindSurrogateMother.com Helping Create Pathways to Parenthood 2Health News:Over 800 New Surrogate Mother Members at FindSurrogateMother.com Helping Create Pathways to Parenthood 3
    ... the prosthesis that has helped thousands of disabled worldwide to ... first centre on foreign soil . ,The Colombian government ... of the artificial limb, to set up base in the ... with a Colombia-based NGO. ,M.K. Mathur of BMVSS ...
    ... disease (STD) has surpassed Neisseria gonorrhea in prevalence among young ... a big menace, researchers say . ,The new ... the 1980s. It can cause inflammation of the urethra (the ... the cervix and the lining of the uterus in women, ...
    ... on less than 50 pence (Rs.40) a day will benefit from ... the number of children who die before their fifth birthday. ... when mothers give birth, a doctor or nurse is available to ... much better chance of survival. ,Groups at a high ...
    ... are weak at mathematics, reading, and writing better watch out ... research suggests that such symptoms may cause students to ... Bachmann of Chappaqua Public Schools in New York, the study ... graders, who completed Sleep Disorders Inventory for Students - Child ...
    ... new genetic cause for Joubert syndrome (JS), an inherited ... brainstem-the structures in the brain that coordinate movements and ... and consciousness. ,This is the fifth gene ... syndrome. Researchers at Seattle Children's Hospital Research Institute, the ...
    ... University of Washington and other members of an international ... genome functions . While previous studies of the human ... insight into the non-gene sequences making up the vast ... non-gene sequences are so-called "regulatory elements" that contain instructions ...
    Cached Medicine News:Health News:Jaipur Foot All Set to Launch Its Centre in Columbia 2Health News:British Funds 250 Million Pounds to Reduce Child Mortality 2Health News:Students With Sleep Disorder Symptoms Score Badly in Maths 2Health News:Boffins Identify Fifth Gene Behind Joubert Syndrome 2Health News:Researchers Cracking the Human Genome Function 2Health News:Researchers Cracking the Human Genome Function 3
    Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Large type 1/1 (mm), opening width 8.0 mm and length 5 mm....
    Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Large type 1/1 (mm), opening width 13.0 mm and length 12 mm....
    Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Standard type 1/1 (mm), opening width 9.0 mm and length 11 mm....
    Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Standard type 1/1 (mm), opening width 9.0 mm and length 9 mm....
    Medicine Products: